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Inflammatory hepatocellular adenomas (IHCA) 
are benign liver tumors that predominantly de-
velop in women and are frequently associated 
with obesity and alcohol abuse (Zucman-Rossi 
et al., 2006; Bioulac-Sage et al., 2007). These 
tumors are characterized by overexpression of 
the acute-phase inflammatory response in tumor 
hepatocytes and highly polymorphous inflam-
matory infiltrates. We recently showed that 60% 
of IHCA activate signal transducer and activa-
tor of transcription 3 (STAT3) via somatic het-
erozygous activating mutations in IL6ST (IL-6 
signal transducer) that encodes the gp130 co- 
receptor and signal transducer of IL-6 family 
cytokines (Rebouissou et al., 2009).
Inflammatory adenoma is a homogenous dis-
ease in which gp130-mutated and nonmutated 
IHCAs are similar in their expression profiles, 
particularly  in  regard  to  the  expression  of 
acute phase inflammatory response target genes 
(Rebouissou et al., 2009). To identify genetic 
alterations  causing  the  inflammatory  pheno-
type, defined as an acute-phase inflammatory 
response with elevated levels of serum amyloid A 
and  C-reactive  protein  (CRP)  observed  in 
nonmutated gp130 IHCA, we used a candidate 
gene strategy. We focused on STAT3, as it en-
codes a key nuclear transcription factor that in-
duces the acute-phase inflammatory response 
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Inflammatory hepatocellular adenomas (IHCAs) are benign liver tumors. 60% of these 
tumors have IL-6 signal transducer (IL6ST; gp130) mutations that activate interleukin  
6 (IL-6) signaling. Here, we report that 12% of IHCA subsets lacking IL6ST mutations 
harbor somatic signal transducer and activator of transcription 3 (STAT3) mutations (6/49). 
Most of these mutations are amino acid substitutions in the SH2 domain that directs 
STAT3 dimerization. In contrast to wild-type STAT3, IHCA STAT3 mutants constitutively 
activated the IL-6 signaling pathway independent of ligand in hepatocellular cells. Indeed, 
the IHCA STAT3 Y640 mutant homodimerized independent of IL-6 and was hypersensitive 
to IL-6 stimulation. This was associated with phosphorylation of tyrosine 705, a residue 
required for IL-6–induced STAT3 activation. Silencing or inhibiting the tyrosine kinases 
JAK1 or Src, which phosphorylate STAT3, impaired constitutive activity of IHCA STAT3 
mutants in hepatocellular cells. Thus, we identified for the first time somatic STAT3 muta-
tions in human tumors, revealing a new mechanism of recurrent STAT3 activation and 
underscoring the role of the IL-6–STAT3 pathway in benign hepatocellular tumorigenesis.
© 2011 Pilati et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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nucleotide mutations were carried by the same allele. We also 
showed in three different cases (#379, #966, and #1351) that 
the mutations were harbored by all of the isoforms of STAT3, 
including splicing of nucleotides 2099–2101 and 2145–2194 
(STAT3) that lead to p.Ser701del and p.Thr716PhefsX8,   
respectively (Fig. S1 C; Schaefer et al., 1995). Sequencing 
STAT3 RT-PCR products in mutated tumors showed that all 
cases  expressed  the  normal  and  mutated STAT3  alleles  at 
comparable levels (Fig. S1, A and B). Thus, the expression of 
one mutated STAT3 allele is a rare but recurrent genetic 
event in IHCA that is selected for during benign hepatocel-
lular tumorigenesis.
Four of the seven identified mutations were located in the 
domain of STAT3 (residues 585–688) that shares homology 
with Src homology 2 (SH2) domains (Fig. 1 A). The STAT3 
SH2 domain mediates STAT3 dimerization via binding of 
phosphotyrosine residue Y705 (Shuai et al., 1994; Wen et al., 
1995). Moreover, three of these mutations clustered in a hot-
spot in the SH2 domain at codons 657 and 658. Interestingly, 
introduction of cysteine at residues 662 and 664 promotes 
STAT3 dimerization and creates a constitutively active tran-
scription factor (Stat3-C; Bromberg et al., 1999). The fourth 
mutation,  Y640F, was in the PYTK motif conserved in STAT1, 
STAT2, and STAT3. Interestingly, substitution of the corre-
sponding Y631 to phenylalanine in STAT2 promotes type I 
IFN signaling (Scarzello et al., 2007; Constantinescu et al., 
2008). The three other mutations found in IHCA were dis-
tributed throughout the protein: the altered leucine-78, which 
contributes to dimerization (Chen et al., 2003); glutamate-
166, which is part of helix 1 involved in the interaction with 
gp130 (Zhang et al., 2000a); and aspartate-502, which is lo-
cated in the -helical “connector” domain. Remarkably, none 
of the mutations identified in IHCA were similar to the 150 
germline-inactivating  STAT3  heterozygous  mutations  de-
scribed in patients with Job’s syndrome, which causes hyper-IgE 
syndrome (Holland et al., 2007; Minegishi et al., 2007).
IHCA mutations activate STAT3 in absence of IL-6
To  investigate  possible  functional  consequences  of  these 
STAT3 IHCA mutations, we introduced the seven different 
IHCA mutations into a STAT3 (full-length) cDNA and an-
alyzed their effects in Hep3B cells, a hepatocellular carcinoma 
line that activates the acute inflammatory phase after treatment 
in hepatocytes. Moreover, STAT3 has oncogenic roles in epi-
thelial cell tumorigenesis (Grivennikov et al., 2009, 2010;   
Yu et al., 2009). STAT proteins are latent transcription factors ac-
tivated by phosphorylation, typically after the binding of ex-
tracellular ligands to cytokine receptors that activate associated 
JAK kinases via growth factor receptors having intrinsic tyro-
sine kinase activity (e.g., epidermal growth factor receptor, 
platelet-derived growth factor receptor, and colony stimulat-
ing factor 1 receptor), as well as by nonreceptor tyrosine ki-
nases such as Src family kinases (Levy and Darnell, 2002). 
STAT3, one of seven STAT family members, is activated by 
gp130 in response to IL-6 (Zhong et al., 1994; Inoue et al., 
1997). STAT3 is persistently phosphorylated in many human 
cancer cell lines and in epithelial cells and primary tumors, 
including hepatocellular carcinoma, breast, prostate, and head 
and neck cancers, and also in several hematological malignan-
cies. STAT3 mutations have never been described in human 
tumors, yet we reasoned that alterations activating its function 
would explain the inflammatory phenotype of IHCA lacking 
mutations in gp130.
RESULTS AND DISCUSSION
Identification of STAT3 mutations in IHCA
Among 114 screened hepatocellular adenomas, we identified 
7 STAT3 mutations in 6 tumors (Table I and Fig. S1, A and B). 
All of these adenomas were inflammatory (6 out of 75 IHCA), 
and no additional somatic mutations were identified in hepa-
tocyte nuclear factor 1 (HNF1A), catenin (cadherin-associated pro-
tein), 1 (CTNNB1), or IL6ST, genes that are recurrently 
altered in IHCA and HCA (Bluteau et al., 2002; Zucman-
Rossi et al., 2006; Rebouissou et al., 2009). Thus, STAT3 
IHCA mutations are exclusive from all other known genetic 
alterations in hepatocellular tumors. STAT3-mutated IHCA 
were associated with obesity (n = 4) and/or alcohol abuse 
(n = 3), and multiple (≥4) nodules were present in half of 
these cases. All STAT3 mutations were somatic, as they were 
not observed in adjacent nontumor liver tissues that were ste-
atotic in 5/6 cases. All mutations were also monoallelic and led 
to amino acid substitutions in 5 cases or to in-frame insertions 
of 1–4 aa in the remaining 2 cases. In one case (#379), we 
identified 3 nucleotide mutations that led to amino acid sub-
stitutions at codons 502 and 658. Sequencing cloned STAT3 
cDNA from this tumor showed that the three different   
Table I.  STAT3 somatic mutations identified in inflammatory hepatocellular tumors
Tumors Nucleotide change Amino acid change Mutant ID
CHC341T T233>G L78>R L78
CHC379T G1504>T D502>Y D502
A1972>T; G1974>T K658>Y K658
CHC574T G496>C E166>Q E166
CHC966T A1919>T Y640>F Y640
CHC1021T T1969_G1980dup Y657_M660dup Y657
CHC1351T C1968>T; 1969_1970insTTT G656_Y657insF G656
Codons and mutated nucleotides are numbered according to STAT3 cDNA open reading frame.JEM Vol. 208, No. 7  1361
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activate STAT3, but cooperates with the mutation at K658 
present in the SH2 domain.
IHCA STAT3 mutants are constitutively phosphorylated  
on Tyr705 and translocate to the nucleus
STAT3 activation requires phosphorylation of tyrosine 705, 
dimerization, and translocation to the nucleus. Accordingly, in 
STAT3-mutated IHCA, immunohistochemical analyses dem-
onstrated marked overexpression of phospho-Tyr705-STAT3 
in the nucleus of these tumor hepatocytes (Fig. 2 A). Similarly, 
in Hep3B-transfected cells, we showed that the STAT3 mu-
tants L78R, E166Q,  Y640F, and G656_Y657insF were consti-
tutively phosphorylated on Tyr705 and translocated to the 
nucleus, whereas overexpressed WT was unphosphorylated 
and cytoplasmic in the absence of cytokine (Fig. 2, B–D). 
STAT3 IHCA mutants did not exhibit increased phosphory-
lation of serine 727, a second residue involved in STAT3 acti-
vation (Wen et al., 1995), when compared with IL-6–activated 
WT (Fig. S2 A). Moreover, in STAT3 Y640 and G656 mutants, 
with IL-6 (Coulouarn et al., 2005). The results were also vali-
dated in two additional hepatocellular cell lines (HepG2 and 
Huh7). As previously described (Bromberg et al., 1999), in 
the absence of IL-6 ligand and serum, overexpression of WT 
STAT3 (WT) alone was not sufficient to activate a STAT3 
reporter (Fig. 1 B) or the downstream acute-phase inflamma-
tory genes (Fig. 1 C). In contrast, the six IHCA mutants and 
the mouse Stat3-C mutant (Bromberg et al., 1999) activated 
the STAT3 reporter in the absence of IL-6 and induced tar-
gets typical of the acute inflammatory response, including 
CRP and SOCS3 (Fig. 1, B and C). Moreover, activation of 
STAT3 was proportional to the amount of the transfected 
mutant STAT3 (Fig. 1 D). The last IHCA mutant D502Y/
K658Y, identified in tumor #379, has two mutations on the 
same allele. The D502Y mutation did not impart constitutive 
activity, whereas K658Y activated the inflammatory response. 
Additionally, the dual mutant (D502Y + K658Y) produced a 
hyperactive  STAT3  mutant  compared  with  K658Y  alone 
(Fig. 1 E). Thus, mutation at D502 alone is not sufficient to 
Figure 1.  Gain-of-function mutations in STAT3 in IHCA. (A) Distribution of STAT3 mutations identified in IHCA is represented according to the 
different protein domains. Asterisk indicates the two mutations that are found on the same allele in tumor #379. Stat3-C location is indicated in gray.  
(B) STAT3 mutants L78R (L78), E166Q (E166), Y640F (Y640), D502Y K658Y (D502/K658), G656_Y657insF (G656), Y657_M660dup (Y657), and Stat3-C (SC) or control 
STAT3 WT (WT) and empty plasmid (EP) were transfected in Hep3B, HepG2, and Huh7 cells expressing a STAT3-driven luciferase (Luc) reporter construct. 
STAT3 activation was measured after 6 h of serum starvation and, when indicated, was treated for 3 h with 100 ng/ml IL-6. Shown is the Luc activity 
(mean) determined from triplicate co-transfections (± SD) relative to pSIEM-luc alone (EP) without IL-6. (C) Graphs are qRT–PCR results showing the in-
duction of endogenous CRP, STAT3, and SOCS3 mRNA after overexpression of mutant STAT3 relative to unstimulated EP-transfected Hep3B cells (EP; 
mean ± SD). (D) Endogenous CRP mRNA expression in Hep3B cells transfected with increasing amounts of expression plasmids encoding WT or E166 STAT3 
mutant (dotted line: mock-transfected cells). (E) Activity of the STAT3 mutants, including D502Y (D502), K658Y (K658), and the double mutant D502Y K658Y 
(D502/K658) were evaluated using STAT3-driven Luc in Hep3B cell line. Data are from triplicate transfections (± SD) relative to pSIEM-luc alone (EP). *, P < 0.05; 
**, P < 0.01; ***, P < 0.001, two-tailed Student’s t test.1362 Activating STAT3 mutations in hepatocellular adenoma | Pilati et al.
slightly  increases  tyrosine  705  phos-
phorylation (Haan et al., 2000). In ad-
dition, overexpression of WT impaired 
the  activity  of  the  STAT3  mutant 
Y640F  in  a  dose-dependent  manner 
(Fig. 3 B). Thus, WT can compete with 
the mutant STAT3 and impair the for-
mation  of  active  IHCA  mutant  ho-
modimers. Interestingly, analysis of the 
STAT3 homodimer structure (Becker 
et al., 1998) showed that 4 out of 6 
STAT3 mutants targeted amino acids 
(Y640, K658, Y657, and Y657-M660) 
that reside near the transcription activation domain (TAD; res-
idues 701–722; Fig. 3 C and Fig. S2 B). For example, Tyr-640 
engages in hydrophobic interactions with twofold related Phe-
710 and residues 656–659 pack against TAD residues 711–716 
(Fig. 3 C and Fig. S2 B). These modifications could thus en-
hance mutant STAT3 function, and they must also somehow 
facilitate phosphorylation of tyrosine 705 by kinases in hepa-
tocytes,  which  would  then  drive  dimerization  and  nuclear   
localization of mutant STAT3. After cytokine exposure, phos-
phorylated  STAT3  homodimers  translocate  to  the  nucleus 
where they bind to specific IL-6–responsive elements to acti-
vate the transcription of target genes (Hattori et al., 1990). In 
Hep3B cells, nuclear Y640 and G656 STAT3 mutants bind to 
recognition  elements  found  in  endogenous  STAT3  target 
genes in the absence of IL-6, whereas, as expected, WT was 
defective in binding in the absence of IL-6 (Fig. 3 D).
substitution of tyrosine 705 with phenylalanine totally abro-
gated activation of the inflammatory response. Thus, tyrosine 
phosphorylation is essential for activation of IHCA mutant 
STAT3 (Fig. 2 E).
IHCA STAT3 mutants dimerize in absence of cytokine
A critical step in STAT3 activation is the formation of ho-
modimers through reciprocal phospho-Tyr705–SH2 domain 
interactions. To assess dimerization by IHCA STAT3 mutants, 
we performed coimmunoprecipitation assays with epitope-
tagged STAT3 proteins. The  Y640F mutant homodimerized or 
heterodimerized with WT independent of IL-6 (Fig. 3 A). 
Moreover, mutant homodimers were highly phosphorylated at 
tyrosine 705. In contrast, homodimers of WT were only faintly 
detected and were not phosphorylated on tyrosine 705. As ex-
pected, IL-6 treatment does not enhance dimer formation, but 
Figure 2.  Subcellular localization and 
role of tyrosine 705 phosphorylation in 
STAT3 IHCA mutants. (A) Immunochemistry 
of phospho-STAT3-Y705 in STAT3-mutated 
IHCA and adjacent nontumor liver (NTL).  
(B–D) Vectors driving the expression of STAT3 
mutants, including L78R (L78), E166Q (E166), 
Y640F (Y640), G656_Y657insF (G656), or WT 
(WT) STAT3, were transfected into Hep3B cells. 
(B) Expression of total and phosphorylated 
(pY705) STAT3 proteins were assessed by 
Western blot and bands were quantified with 
ChemiDoc using the Quantity One software; 
bars show the expression of pY705 STAT3 
relative to total STAT3. (C and D) Subcellular 
localization of total and phosphorylated 
(pY705) STAT3 proteins were analyzed by 
Western blot (C) and by immunofluorescence 
(D). Results are representative of three inde-
pendent experiments. Bars, 20 µm. (E) CRP 
mRNA expression after transfection of WT, 
Y705F (Y705), Y640F (Y640), Y640F/Y705F (Y640/
Y705), G656_Y657insF (G656), or G656_
Y657insF/Y705F (G656/Y705) STAT3 in unstimu-
lated Hep3B cells. Data are from triplicate 
transfections (± SD) relative to EP. *, P < 0.05; 
**, P < 0.01; ***, P < 0.001, two-tailed Stu-
dent’s t test.JEM Vol. 208, No. 7  1363
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by Src family kinases or via Jak1 (in NIH 3T3 cells) as an 
intermediate kinase between Src and STAT3 (Zhang et al., 
2000b). Our findings suggest that in hepatocellular cell lines, 
the requirement of Jak1 is necessary for maximal activation of 
IHCA STAT3 mutants, whereas Src is essential for their con-
stitutive activation.
STAT3-mutated IHCA are similar to gp130-mutated IHCA
In vivo, expression analyses of 16 IHCA revealed no signifi-
cant differences in 28 target genes of IL-6 and IFN signaling 
pathways in STAT3-mutated adenomas (n = 5) versus gp130-
mutated IHCA (n = 11; Fig. 4 G). Thus, the functional effects 
of mutating STAT3 and gp130 in human hepatocellular ade-
nomas appear redundant.
In the liver, activation of the IL-6–STAT3 signaling is 
necessary for the acute-phase response during inflammation 
(Lütticken  et  al.,  1994)  and  liver  regeneration,  particularly   
after transplantation (Cressman et al., 1996). The connection 
between inflammation and tumorigenesis has been extensively 
investigated  over  the  past  decade  (Grivennikov  and  Karin, 
2010).  Depending  of  the  model,  inflammation  can  trigger   
tumor initiation or function to enhance tumor progression 
and/or metastasis. During these processes and in numerous 
tumor types, STAT3 activation has been recognized as a major 
oncogenic event. However, in our cohort, STAT3-activating 
mutations were found in 8% of the inflammatory hepatocel-
lular adenoma, but were not present in a series of 218 malig-
nant liver tumors, including hepatocellular carcinomas and 
cholangiocarcinomas (n = 11). Thus, STAT3-activating muta-
tions appear to be largely or quasiexclusively associated with 
benign proliferation of hepatocytes in human.
IHCA STAT3 mutants are hyperresponsive to IL-6
To investigate the role of the IL-6–JAK pathway in the activa-
tion status of IHCA STAT3 mutants, we tested the effects of 
increasing doses of IL-6 on their activity. Indeed, even low 
doses of IL-6 (1 ng/ml) dramatically augmented the constitu-
tive activity of the Y640 STAT3 mutant compared with the 
WT (Fig. 4 A). This hypersensitive response to IL-6 signaling 
was  confirmed  for  L78,  E166,  G656,  and Y657  STAT3   
mutants (Fig. 4 B and Fig. S2 C). Together with gp130, JAK1 
is known as the major kinase that phosphorylates and acti-
vates STAT3 in IL-6 signaling. Accordingly, silencing JAK1 
using small interfering RNA (siRNA) abolished the hyper-
stimulation of the STAT3 mutants by IL-6 (Fig. 4 B).
Activity of IHCA STAT3 mutants requires Src
In the absence of IL-6 signaling, silencing of gp130 or JAK2 
did not affect the constitutive activity of IHCA STAT3 
mutants (Fig. 4, C and D). In contrast, JAK1 knockdown by 
siRNA partially impaired constitutive IHCA STAT3 mutant 
activity (Fig. 4 E). Similarly, AG490, an inhibitor that disables 
the kinase activity of both JAK1 and JAK2; Ruxolitinib, a se-
lective inhibitor of Jak1; and curcumin, a STAT3 inhibitor, 
partially decreased the activity of IHCA STAT3 mutants 
(Fig. S3, A and B). In contrast, treatment with SrcI-1 kinase 
inhibitor dramatically impaired both the constitutive and   
IL-6–induced activation of IHCA STAT3 mutants (Fig. 4 F 
and Fig. S3 C). Two other Src kinase inhibitors also impaired 
the activity of IHCA STAT3 mutants (Fig. S3, D and E). Thus, 
phosphorylation and activation of mutant STAT3 does not 
require gp130 or JAK2 but requires JAK1 and Src signaling. 
Depending on cell context, STAT3 can be activated directly 
Figure 3.  Dimerization of STAT3 IHCA mutants.  
(A) Flag- and Myc-tagged constructs encoding either WT or 
mutant Y640 STAT3 were co-transfected (1:1) into Hep3B 
cells treated, or not treated, with 100 ng/mlIL-6. STAT3 dimer 
formation was detected after immunoprecipitation using the 
anti-Flag antibody, followed by immunoblot (IB) analysis 
with Myc, Flag, and pY705-STAT3–specific antibodies. Results 
are representative of three independent experiments.  
(B) Effects of increasing WT STAT3 expression (wedge) on the 
constitutive activity of Y640 mutant STAT3 without IL-6. The 
graph plots the mean level of expression of SOCS3 and CRP 
relative to cells transfected with EP (± SD). Units are plasmid 
micrograms. (C) Several STAT3 IHCA mutations cluster near 
the TAD of STAT3 (crystal structure; NCBI Protein database 
accession no. 1BG1; Becker et al., 1998). Residues 640 and 
656–660 (shown in green), which are mutated in IHCA tu-
mors, the phosphorylated tyrosine (Tyr-705, black), and TAD 
residues 711–716 (blue), are shown in stick representation. 
One polypeptide chain and both TADs are shown as a car-
toon. The twofold related molecule, except the TAD, is shown 
as a surface representation. For residues of the TAD, Tyr-710 
of the twofold related molecule is labeled, whereas residues 
711–716 are not, for clarity. (D) DNA-binding activity of 10 µg 
of nuclear extracts of Hep3B cells engineered to express WT, Y640, or G656 STAT3 mutants. Bars indicate the DNA-binding activity to consensus STAT3 
oligonucleotides relative to activity measured in cells transfected with EP. *, P < 0.05; **, P < 0.01; ***, P < 0.001, two-tailed Student’s t test. Data are from 
triplicate transfections (±SD).1364 Activating STAT3 mutations in hepatocellular adenoma | Pilati et al.
MATERIALS AND METHODS
Tumors and patients. A series of 364 hepato-
cellular tumors, including 114 HCAs, 218 com-
mon  hepatocellular  carcinomas  (HCCs),  11 
cholangiocarcinomas and 20 hepatocholangio-
carcinomas were previously collected (according 
to French ethical guidelines) and characterized 
(Bioulac-Sage et al., 2007; Zucman-Rossi et al., 2006). In brief, patients with 
HCA were predominantly female (80%) with a mean age of 39 yr; among 
them, 13% presented mutations of CTNNB1 gene, 19% presented mutations 
of HNF1, 26% displayed IHCA-associated IL6ST mutations, 39.5% showed 
IHCA without IL6ST mutations, and 9.6% were nonclassified adenomas. 
Patients with HCC were predominantly male (79%), with a mean age of 64 yr, 
and 34.3% of these presented with cirrhosis. The underlying risk factors of 
patients with HCC were chronic hepatitis B (19%), chronic hepatitis C (25%) 
and heavy alcohol intake (38%). Patients with cholangiocarcinoma were pre-
dominantly male (72%) and were slightly younger (mean age, 61 yr) than pa-
tients with common HCC. Patients with hepatocholangiocarcinoma were 
also predominantly male (89%) and had a median age of 61 yr. All patients 
have given consent according to French law, and the ethical committee of 
Saint Louis Hospital approved the study.
Tumor and nontumor liver samples were frozen immediately after sur-
gery or biopsy and stored at –80°C. Tissues samples were also included in 
10% formalin, paraffin-embedded and stained with hematin-eosin and 
Masson’s trichrome. The diagnosis of HCA, HCC, cholangiocarcinoma, 
Collectively, our findings show that most of the genetic 
alterations of HCA subtypes (HNF1A inactivation, -catenin 
activation, or activation of STAT3 via mutation of STAT3   
or gp130), are associated with benign hepatocyte tumorigen-
esis, where there remains a largely controlled rate of tumor 
cell  proliferation.  At  present,  only  -catenin–activating   
mutations are associated with malignant transformation to 
hepatocellular carcinoma (Zucman-Rossi et al., 2006), and 
here there are likely additional cooperating mutations that 
lead to frank malignancy. Regardless, to our knowledge this 
is  the  first  identification  of  somatic  mutation  of  STAT3  
in human tumors, and these findings underscore the impor-
tant  role  of  STAT3  activation  in  hepatocellular  benign   
tumorigenesis and reveal a new mechanism of recurrent 
STAT3 activation.
Figure 4.  Role of IL-6–JAK pathway and 
Src kinases on STAT3 IHCA mutant activa-
tion. STAT3 mutants Y640 and E166 were over-
expressed in Hep3B cells. Activation of STAT3 
is shown by Luc activity (mean) determined 
from triplicate transfections (± SD) relative to 
pSIEM-luc alone (EP) with serum starvation. 
(A) Hep3B cells were exposed to increasing 
concentrations of IL-6. (B) STAT3 mutants 
(E166 and Y640) or empty vector (EP) were co-
transfected with JAK1 siRNA (+) or control 
siRNA () into Hep3B cells exposed to  
100 ng/ml IL-6. (C) STAT3 mutants (E166 and 
Y640) or empty vector (EP) were co-transfected 
with gp130 siRNA (+) or control siRNA () 
into Hep3B cells. (D) STAT3 mutants (E166 and 
Y640) or empty vector (EP) were co-transfected 
with JAK2 siRNA (+) or control siRNA () into 
Hep3B cells. (E) STAT3 mutants (E166 and Y640) 
or empty vector (EP) were co-transfected with 
JAK1 siRNA (+) or control siRNA (v) into 
Hep3B cells. (F) STAT3 mutants (E166 and Y640) 
or empty vector (EP) were transfected into 
Hep3B cells exposed to Src inhibitor 1 (SrcI-1; 
10 µM; 9 h). *, P < 0.05; **, P < 0.01; ***, P < 
0.001, two-tailed Student’s t test. Data are 
from triplicate transfections (± SD). (G) Ex-
pression profiles of STAT3-mutated IHCA and 
gp130-mutated IHCA. Comparison was per-
formed for the 28 genes validated by qRT-PCR 
that were significantly differentially expressed 
between IHCA and nontumorous livers.  
5 STAT3-mutated IHCAs (black) were com-
pared with 11 gp130-mutated IHCAs (in 
white). Results are expressed as mean ± SD; 
differences between groups are not signifi-
cant (two-tailed Mann-Whitney test).JEM Vol. 208, No. 7  1365
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Signaling Technology; 1:500) and phospho-STAT3 Tyr705, (Cell Signaling 
Technology; 1:200). For dimerization assays, cell lysates were incubated with 
Immobilized Protein G agarose (Thermo Fisher Scientific) and anti-flag 
(Cell Signaling Technology; 1:50) or anti-myc (Cell Signaling Technology; 
1:200) antibody, at 4°C overnight, before Western blot analysis.
Immunohistochemistry. Immunohistochemistry was performed using a 
Dako autostainer, on paraffin sections of 10% fixed tumor tissue using a 
monoclonal anti–phospho-STAT3 Tyr705 (Cell Signaling Technology; 1:50). 
For each immunohistochemical procedure, antigen retrieval was performed 
in citrate buffer; detection was amplified by the Dako Envision system.
STAT3 DNA-binding assays. 1 d after transfection, cells were starved in a 
serum-free medium overnight, and the TransFactor Extraction kit (Takara 
Bio, Inc.) was used to prepare nuclear extracts following the manufacturer’s 
protocol. Nuclear extracts were analyzed for STAT3 DNA-binding activity 
using the TransFactor Universal STAT3-specific kits (Takara Bio, Inc.), which 
is an ELISA-based method.
Immunofluorescence. 24 h after transfection, cells were fixed in 4% form-
aldehyde for 15 min, washed with PBS, and permeabilized with 0.1% Triton 
X-100 for 15 min. Cells were saturated with 2% BSA for 30 min, washed 
with PBS, and then incubated with primary antibody overnight at 4°C. After 
3 washes with PBS, cells were incubated with secondary antibodies for 1 h. 
The slides were washed, and then mounted with  VECTASHIELD Mounting 
Medium  with  DAPI  (Vector  Laboratories).  Immunofluorescence  images 
were obtained using an HBO 100 optic microscope (Carl Zeiss, Inc.). All data 
from one experiment were collected at the same intensity and background 
level. The following monoclonal antibodies were used: rabbit anti–phospho-
STAT3 Tyr705 (Cell Signaling Technology; 1:200), mouse anti-total STAT3 
(Cell Signaling Technology; 1:100). The secondary antibodies were anti–
mouse (Invitrogen; 1:200) and anti–rabbit (Invitrogen; 1:200).
Online supplemental material. Fig. S1 shows the somatic DNA alterations 
identified on STAT3 gene, and distribution of mutations according to the dif-
ferent isoforms. Fig. S2 shows serine 727 phosphorylation of STAT3 mutants. 
Fig. S3 shows the effect of inhibitors on STAT3 IHCA mutant activation. 
Table S1 lists the TaqMan predesigned gene expression assays used for qRT-
PCR analyses. Table S2 lists the primers used in PCR and sequencing. Table S2 
lists the primers used in in site-directed mutagenesis. Online supplemental mate-
rial is available at http://www.jem.org/cgi/content/full/jem.20110283/DC1.
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